Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemtabrutinib + Brexu-cel in R/R Mantle Cell Lymphoma
NCT07673367Phase 2Recruiting
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Jul 2026
- Primary completion
- Jul 2031
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nemtabrutinib in mantle cell lymphoma (MCL), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Progression-free survival up to 5 years. Started Jul 2026; status: recruiting.
02
Drugs
nemtabrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT07673367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07673367.